Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC offering is ITURA, an advanced topical cream formulated to alleviate multiple symptoms such as numbness, tingling sensations, muscle cramps, reduced sensitivity, and pain frequently associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has cultivated strategic partnerships with prominent institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Incorporated in 2003, the company, which officially changed its name from Zelda Therapeutics Limited in December 2019, maintains its corporate headquarters in Perth, Australia.
—
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC offering is ITURA, an advanced topical cream formulated to alleviate multiple symptoms such as numbness, tingling sensations, muscle cramps, reduced sensitivity, and pain frequently associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has cultivated strategic partnerships with prominent institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Incorporated in 2003, the company, which officially changed its name from Zelda Therapeutics Limited in December 2019, maintains its corporate headquarters in Perth, Australia.
—
Daily adjusted close
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC offering is ITURA, an advanced topical cream formulated to alleviate multiple symptoms such as numbness, tingling sensations, muscle cramps, reduced sensitivity, and pain frequently associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has cultivated strategic partnerships with prominent institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Incorporated in 2003, the company, which officially changed its name from Zelda Therapeutics Limited in December 2019, maintains its corporate headquarters in Perth, Australia.